EQRx Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

EQRx şirketinin kazançları yıllık ortalama -12.3% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında arttı.

Anahtar bilgiler

-12.3%

Kazanç büyüme oranı

98.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-22.2%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2023

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Gelir ve Gider Dağılımı

EQRx nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:EQRX Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 23	-260	104	204
30 Jun 23	-263	114	240
31 Mar 23	-272	124	244
31 Dec 22	-169	129	227
30 Sep 22	-146	138	211
30 Jun 22	-100	121	179
31 Mar 22	-53	102	153
31 Dec 21	-100	80	116
30 Sep 21	-279	50	229
30 Jun 21	-296	40	256
31 Mar 21	-269	32	237
31 Dec 20	-250	27	223

Kaliteli Kazançlar: EQRX şu anda kârlı değil.

Büyüyen Kar Marjı: EQRX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: EQRX kârlı değildir ve zararlar son 5 yılda yılda 12.3% oranında artmıştır.

Büyüme Hızlandırma: EQRX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: EQRX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: EQRX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -22.23% ) sahiptir.

EQRx Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

EQRx, Inc. Files Form 15

EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

New minor risk - Share price stability

We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the Uk's Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-Small Cell Lung Cancer

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

High number of new and inexperienced directors

We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs

EQRx GAAP EPS of -$0.17 beats by $0.03

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

EQRx, Inc., Annual General Meeting, Sep 30, 2022

Eqrx Announces Acceptance of Marketing Authorization Application by U.K.'s Medicines and Healthcare Products Regulatory Agency for Aumolertinib

EQRx, Inc. Announces New Data for Lead Oncology Programs in Non-Small Cell Lung Cancer

High number of new and inexperienced directors

We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

High number of new and inexperienced directors

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

No independent directors

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

EQRx Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

EQRx, Inc. Files Form 15

EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

New minor risk - Share price stability

We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the Uk's Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-Small Cell Lung Cancer

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

High number of new and inexperienced directors

We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs

&nbsp;EQRx GAAP EPS of -$0.17 beats by $0.03

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

EQRx, Inc., Annual General Meeting, Sep 30, 2022

Eqrx Announces Acceptance of Marketing Authorization Application by U.K.'s Medicines and Healthcare Products Regulatory Agency for Aumolertinib

EQRx, Inc. Announces New Data for Lead Oncology Programs in Non-Small Cell Lung Cancer

High number of new and inexperienced directors

We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

High number of new and inexperienced directors

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

No independent directors

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

EQRx GAAP EPS of -$0.17 beats by $0.03